Barclays Lowers Bruker (NASDAQ:BRKR) Price Target to $65.00

Bruker (NASDAQ:BRKR) had its price target reduced by equities researchers at Barclays from $69.00 to $65.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target would suggest a potential upside of 16.93% from the stock’s previous close.

Several other research analysts have also issued reports on the stock. Citigroup cut their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a report on Thursday, December 5th. Bank of America boosted their target price on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. UBS Group began coverage on shares of Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target on the stock. Finally, Wells Fargo & Company cut their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $74.09.

Bruker Trading Down 0.8 %

Shares of Bruker stock opened at $55.59 on Monday. The company has a 50 day simple moving average of $58.32 and a two-hundred day simple moving average of $61.04. The firm has a market cap of $8.43 billion, a PE ratio of 26.73, a PEG ratio of 3.81 and a beta of 1.16. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were purchased at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 28.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the business. True Wealth Design LLC increased its position in Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares during the period. Eagle Bay Advisors LLC boosted its stake in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. increased its position in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the period. GAMMA Investing LLC raised its stake in Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in Bruker in the third quarter worth about $73,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.